Katarzyna Wrzeszcz

Tissue Plasminogen Activator as a Possible Indicator of Breast Cancer Relapse: A Preliminary, Prospective Study

P. Rhone, A. Słomka, B. Ruszkowska-Ciastek, 2022, Journal of clinical medicine.

Hypercoagulability State Combined with Post-Treatment Hypofibrinolysis in Invasive Breast Cancer: A Seven-Year Follow-Up Evaluating Disease-Free and Overall Survival

P. Rhone, B. Ruszkowska-Ciastek, K. Kwiatkowska, 2023, Life.

Traditional Clinicopathological Biomarkers Still Determine Disease-Free and Overall Survival in Invasive Breast Cancer Patients: A Pilot Study

D. Formanowicz, P. Rhone, B. Ruszkowska-Ciastek, 2024, Journal of clinical medicine.

Unraveling the Angiogenic Puzzle: Pre-Treatment sVEGFR1 and sVEGFR2 Levels as Promising Prognostic Indicators in Early-Stage Breast Cancer Patients

P. Rhone, B. Ruszkowska-Ciastek, E. Zarychta, 2023, International journal of molecular sciences.

High Post-Treatment Leptin Concentration as a Prognostic Biomarker of the High Risk of Luminal Breast Cancer Relapse: A Six-Year Comprehensive Study

P. Rhone, B. Ruszkowska-Ciastek, K. Kwiatkowska, 2022, Life.